TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company
Transcenta, Biologics, Antibody, Claudin 18.2
2018 - 03 - 02
Hangzhou, China | March 3, 2018 - HJB, an organization dedicated to expanding global access to important protein therapeutics, recently announced the establishment of its Center of Clinical Development (“the Center”) based in Boston. Following the opening of the R&D Center and Manufacturing Facility in Hangzhou in January, it is a significant step for HJB to further biologics development, accelerate regulatory filing and increase global cooperation.
HJB’s co-founder and president Dr. Jonathan Zhao commented on the reason for establishing the Center and its positioning: “HJB’s goal has always been to grow globally. The Center of Clinical Development in Boston is a key platform for HJB to access US talent and innovation, while providing strong support for HJB’s development needs.”
HJB plans to bring multiple innovative biologics into clinical trials in 2018 and 2019, with potential indications in orphan diseases, cancer and immunology. Boston is at the forefront of the biopharmaceutical industry, being home to many of the top companies and research institutions. The choice of Boston as the home for HJB’s Center is, therefore, a major step in HJB’s global plans.
On January 22 this year, HJB’s R&D Center and Manufacturing Facility officially opened in Hangzhou. The Center in Boston will facilitate co-operation between HJB’s China and US teams. This cross-border exchange not only enables synergies in R&D resources, but will also help in accelerating the global development and filling of HJB’s various assets.
FDA Grants Transcenta Clearance to Proceed with Global Phase III Trial of Osemitamab (TST001) as First-Line Treatment for Gastric/Gastroesophageal Cancer Patients
Transcenta Anti-sclerostin Monoclonal Antibody TST002 (Blosozumab) Received Approval from China CDE to Initiate Phase II Clinical Trial in Patients with Reduced Bone Mineral Density
Transcenta Received Approvals from China CDE and South Korea MFDS to Initiate TranStar 301 Global Phase III Pivotal Trial of Osemitamab (TST001)
Transcenta Presented PFS Data by CLDN18.2 Expression Level from Phase I/II Study of Osemitamab (TST001) plus CAPOX as the First-Line Treatment of Advanced G/GEJ Cancer at 2023 ESMO GI Annual Congress
Transcenta Presents Updated Data of Osemitamab (TST001) in Combination with CAPOX as a First-Line Treatment of G/GEJ Cancer at 2023 ASCO Annual Meeting
Transcenta Announces Encouraging Phase I Clinical Data of TST002 (Blosozumab) in Chinese Patients with Reduced Bone Mineral Density